New medical therapies on the horizon: oral octreotide.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
acromegaly 15 endocrinologydiseases
Octreotide 3 endocrinologydiseasesdrugs
Pasireotide 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Octreotide 1701 currently being conducted. The potential place in the treatment of acromegaly is discussed.Introduction Octreotide is an analog of the natural somatostatin with high binding affinity for the SSTR2 and moderate binding
Octreotide 2082 (inhibiting) are key players in the regulation of GH synthesis, basal and pulsatile secretion in physiology. Octreotide was introduced for the treatment of acromegaly in the 80 s. Initially, only short acting subcutaneous
Octreotide 5085 (TPE) consisting of among others medium-chain free fatty acids, sodium caprylate, inert excipients. Octreotide is encapsulated in an enteric coating, preventing breakdown before reaching the small intestine. The
Pasireotide 4330 subset of adenomas that is truly SRL resistant, usually because SSTR2 expression is lacking or low. Pasireotide , an SRL with increased affinity for SSTR5 and other SSTRs may have additive values over octreotide or
Select Disease Character Offset Disease Term Instance
acromegaly 273 (ppub): /2017AbstractSomatostatin analog treatment is first line medical treatment in patients with acromegaly . This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide.
acromegaly 786 preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly . Maintenance of control in 155 participating patients was achieved in 65% at the end of core period.
acromegaly 1665 administrations. A second phase III study is currently being conducted. The potential place in the treatment of acromegaly is discussed.IntroductionOctreotide is an analog of the natural somatostatin with high binding affinity
acromegaly 2129 synthesis, basal and pulsatile secretion in physiology. Octreotide was introduced for the treatment of acromegaly in the 80 s. Initially, only short acting subcutaneous preparation were available requiring a three-daily
acromegaly 2520 i.e. octreotide and lanreotide, strongly suppress GH release in healthy controls and in patients with acromegaly .Somatostatin analogs are first line medical treatment of acromegaly [[1]]. The long-term efficacy and
acromegaly 2588 healthy controls and in patients with acromegaly.Somatostatin analogs are first line medical treatment of acromegaly [[1]]. The long-term efficacy and safety have been evaluated in landmark studies, open label studies
acromegaly 9768 profound suppression during oral octreotide, throughout the entire study period.Clinical control of acromegaly related symptoms (headache, asthenia, perspiration, swelling of extremities and joint pain) improved
acromegaly 10232 improved the symptom severity score. Also the proportion of subjects with at least one, two, or three acromegaly symptoms decreased from 79, 63, and 45%, respectively, at baseline on injectables to 68, 48, and 31%
acromegaly 14769 whether these factors are of clinical relevance.Potential place of oral octreotide in the treatment of acromegaly At present oral octreotide capsules are an investigational drug, therefore the place in the treatment
acromegaly 16019 study the patient perspective on use of injectables was explored in the chronically treated cohort of acromegaly patients [[13]]. Many patients have active symptoms while on injectables and some reported aggravation
acromegaly 16679 monitored probably more intensively than treatment with injectables to prevent episodes of uncontrolled acromegaly . On the other hand it will provide patients tools to prevent the experienced instability in control
acromegaly 17934 are likely multifactorial.It is important to note that also any chosen biochemical endpoints of any acromegaly trials and trial methodology impact efficacy rates, because patients classified as controlled may be
acromegaly 19917 tools, i.e. SAGIT, try to help physicians to optimally score the several aspects important for care in acromegaly [[16]].It is likely that the patient perspective and patient voice will gain more and more attention
acromegaly 20052 the patient perspective and patient voice will gain more and more attention in the chronic care of acromegaly as is in other chronic (endocrine) diseases and in view of an individualized approach in management
acromegaly 20213 view of an individualized approach in management the possibility of an effective oral treatment in acromegaly will be welcomed as an additional option for a yet unknown subset of patients [[17]]

You must be authorized to submit a review.